Studies: Deferasirox in iron overload after allogeneic hematopoietic cell transplantationID TrialCICL670ADE02EudraCT number2006-003970-89DescriptionA one-year, open-label, single arm, multi-center trial evaluation the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to twelve month after allogeneic hematopoietic cell transplantation in whom iron overload is present. StatusclosedDisease
SponsorNovartisRoonstr. 25 90429 Nürnberg Germany Coordinating investigatorNo dataPrincipal investigator
Study nurse
|
|
